A cost-utility analysis of interferon beta for multiple sclerosis.
Parkin
D
D
School of Health Sciences, University of Newcastle-upon-Tyne, UK.
McNamee
P
P
Jacoby
A
A
Miller
P
P
Thomas
S
S
Bates
D
D
D000276:Adjuvants, Immunologic / Q000191:economics* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D016527:Drug Costs; D005260:Female; D006304:Health Status; D006801:Humans; D016899:Interferon-beta / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D017059:Models, Econometric; D009103:Multiple Sclerosis / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care; D019057:Quality-Adjusted Life Years; D006113:United Kingdom
D000276:Adjuvants, Immunologic; D016899:Interferon-beta